Sakar Healthcare Q1FY26 Profit Jumps 94% YoY; Appoints Three New Independent Directors

Ahmedabad, July 25 — Sakar Healthcare Ltd (NSE: SAKAR) reported a robust 94% year-on-year (YoY) increase in standalone net profit at ₹467.13 lakh for the quarter ended June 30, 2025 (Q1FY26), up from ₹241.20 lakh in Q1FY25, driven by higher operational revenues and improved margins.

Financial Highlights (Standalone)

• Revenue from operations for Q1FY26 stood at ₹5,273.62 lakh, up from ₹5,024.18 lakh in Q4FY25 and ₹4,114.77 lakh in Q1FY25.
• Total income was ₹5,313.01 lakh, compared to ₹5,042.40 lakh in the previous quarter and ₹4,160.75 lakh a year ago.
• The company reported a net profit of ₹467.13 lakh, down from ₹576.11 lakh in Q4FY25, but higher than ₹241.20 lakh in Q1FY25.
• Earnings per share (EPS) came in at ₹2.11, compared to ₹2.66 in the last quarter and ₹1.10 in the same quarter last year.

Consolidated Performance

Consolidated results mirror standalone figures due to the company’s only subsidiary, Sakar Oncology Pvt Ltd, having negligible financial impact in Q1FY26.

Key Updates from the Board Meeting

AGM & E-Voting Schedule:

• 21st AGM Date: September 23, 2025 (via VC/OAVM)
• E-Voting Start: September 20, 2025, 9:00 AM
• E-Voting End: September 22, 2025, 5:00 PM
• Cut-off Date: September 16, 2025

Board and Management Appointments

The company has proposed the appointment of three new independent directors, each for a 5-year term starting July 25, 2025, subject to shareholder approval.

• Megha Samdani (DIN: 08956059) is a Company Secretary with qualifications in M.Com, and expertise in legal and taxation matters.
• Reeya Kothari (DIN: 10312461) is an Associate Company Secretary (ACS) with a background in compliance and legal affairs.
• Hiral Patel (DIN: 09719512) holds ACS, MBA (Finance), and LLB degrees, bringing experience in corporate finance.

Senior Management Hires:

• Sudhir Ghule has been appointed as the Chief Operating Officer (COO). He brings over 30 years of experience from companies like Zydus, Cipla, and Sun Pharma, with deep expertise in plant operations and audits.
• Raviraj Karia joins as Senior Vice President – Finance & Accounts. He is a Chartered Accountant and has previously worked with Intas, GVFL, and Claris, specialising in corporate finance.
• Nimesh Suthar has been appointed as Senior Vice President – International Business. He has 25+ years of experience in pharma exports, having worked with Baxter, Dr. Reddy’s, and Troikaa.

Auditor Appointments:

• Secretarial Auditor: M/s Nishant Pandya & Associates (FY26–FY30)
• Cost Auditor: M/s Dalwadi & Associates for FY26

Fund Utilization Update

In June 2025, the company raised ₹8.64 crore via preferential issue (conversion of warrants). Usage details:

• Out of this, ₹154.65 lakh was allocated for loan repayment to SBI, which has been fully utilised.
• ₹709.35 lakh was earmarked for capital expenditure on the oncology unit.
• As of June 30, 2025, ₹184.56 lakh has been utilised, with the remaining amount expected to be deployed within the next six months.

No Defaults or RPTs

• Outstanding debt: Nil
• Defaults: None reported
• Related party transactions: Not applicable in Q1FY26
• Audit qualification: None; unmodified opinion issued

Sakar Healthcare Stock Performance

Sakar Healthcare shares closed at ₹363, which is a 1.44% dip on July 25, 2025. Sakar Healthcare shares gained 10% in the last year, 20% in the year-to-date, and a 0.07% dip in the previous month. The stock opened at ₹361.20 and moved between a high of ₹375.00 and a low of ₹352.15 during the session. The company’s market capitalisation stands at ₹807.67 crore. The stock’s 52-week high is ₹380.80, while the 52-week low is ₹210.10.

About Sakar Healthcare

Sakar Healthcare Ltd is an NSE-listed pharmaceutical manufacturer headquartered in Ahmedabad. It operates across formulation and oncology verticals and exports to over 30 countries. The company was incorporated in 2004 and is ISO 9001:2015 certified.

REF:https://nsearchives.nseindia.com/corporate/SAKAR_25072025121451_Outcome.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations